The UTS2R antibody targets the urotensin II receptor (UTS2R), a G protein-coupled receptor (GPCR) that binds urotensin II (UII), a potent cyclic peptide involved in diverse physiological processes. UTS2R is widely expressed in cardiovascular tissues, the central nervous system, kidneys, and endocrine organs, playing roles in vasoconstriction, blood pressure regulation, inflammation, and cell proliferation. Dysregulation of the UII-UTS2R axis is implicated in pathologies such as hypertension, heart failure, atherosclerosis, and chronic kidney disease, making it a focus for therapeutic research.
UTS2R antibodies are critical tools for studying receptor localization, expression levels, and signaling mechanisms in both normal and diseased states. They enable techniques like immunohistochemistry, Western blotting, and flow cytometry, aiding in the exploration of UTS2R’s tissue-specific functions and interactions. Additionally, these antibodies support drug discovery by identifying receptor modulators or evaluating therapeutic candidates in preclinical models. Challenges in developing UTS2R antibodies include ensuring specificity due to structural similarities among GPCRs and optimizing stability for experimental reproducibility. Recent advances in antibody engineering, such as monoclonal and recombinant formats, have improved their utility in translational research. By elucidating UTS2R’s role in disease pathways, these antibodies contribute to potential diagnostic and therapeutic innovations, particularly in cardiovascular and metabolic disorders.